top of page

Can Psychedelics Be The New Antidepressants?

While psychedelics have been the subject of stigma for many decades, renewed research and interest in this space is rocking the world of psychiatry by offering new effective breakthrough therapies for the treatment of depression amongst a list of other common mental health disorders.

The Scientific American recently published a comprehensive article exploring the growing evidence and use of psychedelics as antidepressants.

"As far as outcomes go, psychedelics in combination with psychotherapy are remarkably efficient at treating depression. Compared to selective serotonin reuptake inhibitors, or SSRIs, the current gold standard in antidepressant medication, psychedelics have a faster effect on patients, sometimes effective with only a single therapy session. On the other hand, anti-depressants often take weeks before a reversal of depression is observed."

"Psychedelics also have a longer-lasting effect than an SSRI regimen. A 2015 study of more than 190,000 Americans demonstrated that past history of psychedelic use decreases the odds of suicidal thoughts or actions over the course of a lifetime, whereas a history of other drug use (such as sedatives or inhalants) increases these risks."


mindful microdosing.jpeg

Mindful Microdosing Course

A 6-Week Self-Guided Journey To Build, Evolve & Deepen Your Mindful Microdosing Practice 



The perspectives and recommendations on this website are not made by a medical professional and should not be considered medical advice. Readers are encouraged to consult their physician before taking any supplements or substances. 


While we believe that psychedelic medicines must be decriminalized, psychedelic substances are still considered  "Schedule I" substances in the US and continue to be subject to strong enforcement across nearly all states. The reader is responsible for checking their local rules and regulations and making informed decisions with all risk considerations. Microdose Guru does not endorse or accept liability for its readers' personal choices.  

bottom of page